Philogen Overview

  • Founded
  • 1996
Founded
  • Status
  • Public
  • Employees
  • 121
Employees
  • Stock Symbol
  • PHIL
Stock Symbol
  • Share Price
  • $15.00
  • (As of Friday Closing)

Philogen General Information

Description

Philogen Spa is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, it derives a majority of revenue from the USA.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
MIL
Primary Office
  • Via Bellaria, 35
  • 53018 Sovicille
  • Italy
+39 0577 00000

Philogen Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Philogen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$15.00 $14.66 $14.07 - $18.70 $608M 40.5M 10K -$0.46

Philogen Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2009 31-Dec-2009
EV 538,180 538,180
Revenue 2,951 2,951 5,447 20,306
EBITDA (15,340) (15,340) (11,999)
Net Income (18,592) (18,592) (15,144)
Total Assets 150,308 150,308 105,129
Total Debt 13,408 13,408 14,736
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Philogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Philogen‘s full profile, request access.

Request a free trial

Philogen Patents

Philogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3660039-A1 Il2 immunoconjugates Withdrawn 30-Nov-2018 00000000000 00
EP-3749372-A1 Edb targeting il-12 compositions Pending 09-Feb-2018 00000000000
CA-3087488-C Edb targeting il-12 compositions Active 09-Feb-2018 000000000
AU-2021203986-A1 Edb targeting il-12 compositions Pending 09-Feb-2018 000000000
JP-2021513536-A Edb-targeted il-12 composition Pending 09-Feb-2018 A61K47/6813
To view Philogen’s complete patent history, request access »

Philogen Executive Team (4)

Name Title Board Seat Contact Info
Dario Neri Ph.D Co-Founder, Chief Executive Officer, CSO & President of the Scientific Advisory Board
Giovanni Neri Ph.D Co-Founder & Director IP rights
Hans Menssen Chief Medical Officer
Duccio Neri Ph.D Co-Founder and Executive Chairman
To view Philogen’s complete executive team members history, request access »

Philogen Board Members (6)

Name Representing Role Since
00000 00000 00 Self Board Member 000 0000
00000000 0000000000 Self Board Member 000 0000
00000000 0000é Self Board Member 000 0000
0000000 000000000 Self Board Member 000 0000
0000000 00000000 Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Philogen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Philogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Philogen‘s full profile, request access.

Request a free trial